Tag: pharmaceuticals

As expect, Varda announced yesterday that it raised $90 million in investment capital following the publication of the results of its first orbital manufacturing mission, where its returnable capsule was used to produce test pharmaceuticals in space that cannot be made on Earth.

Varda announced April 5 it raised a Series B round led by venture firm Caffeinated Capital, with participation from Lux Capital, General Catalyst, Founders Fund and Khosla Ventures. The company has raised $145 million to date. The funding round comes on the heels of the successful conclusion of its first demonstration mission, W-1, on Feb. 21 when the company’s capsule landed at the Utah Test and Training Range. The capsule had been part of a spacecraft launched in June 2023 to test the ability to produce pharmaceuticals in microgravity.

The new funding will allow Varda to scale up production of spacecraft that take advantage of microgravity to produce pharmaceuticals that are not possible or cost-effective to make on the ground.

The company already has a second returnable capsule scheduled for launch this summer on a Rocket Lab Electron rocket.

On March 20, 2024 Varda released the results from its seven-month-long flight of its unmanned capsule, claiming that the technology worked to produce pharmaceuticals in weightlessness that will be better at treating some difficult illnesses such as HIV.

From the abstract of the preprint paper [pdf]:

Despite notable progress in realizing the benefits of microgravity, the physical stability of therapeutics processed in space has not been sufficiently investigated. Environmental factors including vibration, acceleration, radiation, and temperature, if not addressed could impact the feasibility of in-space drug processing. The presented work demonstrates the successful recovery of the metastable Form III of ritonavir generated in orbit. The test samples and passive controls containing each of the anhydrous forms of ritonavir; Form I, Form II, Form III, and amorphous exhibit excellent stability. By providing a detailed experimental dataset centered on survivability, we pave the way for the future of in-space processing of medicines that enable the development of novel drug products on Earth and benefit long-duration human exploration initiatives.

More research is likely required, but I suspect Varda will be able to raise investment capital from this success, since there is a lot of money to be made from pharmaceuticals that can only be produced in weightlessness.